QIAGEN opens new office In Kuala Lumpur as business expands in Malaysia

KUALA LUMPUR, Malaysia, May 29, 2015 -- QIAGEN announced the opening of its new principal office in Malaysia to serve its growing base of customers for Sample to Insight solutions, enabling them to help fight diseases using molecular diagnostics, break new ground in research for the life sciences and pharmaceutical industry, and protect the public through food safety and forensics testing applications.

In an opening ceremony today, QIAGEN Biotechnology Malaysia Sdn. Bhd. (QIAGEN's unit in the country) hosted customers, representatives of the Malaysian and German governments, news media and other distinguished guests to discuss QIAGEN's recent rapid growth and future plans in Malaysia. Among the guests of honour at the event: YB Datuk Dr. Abu Bakar bin Mohamad Diah, Deputy Minister of Malaysia's Ministry of Science, Technology and Innovation (MOSTI), and H.E. Michael Holger, Germany's Ambassador to Malaysia.

"Opening this new office marks a milestone for QIAGEN. We have grown rapidly in Malaysia since 2006. Our expansion is gaining momentum as we serve Malaysia's doctors, hospitals and diagnostic laboratories, university researchers, growing biotech and pharma industry, and other labs," said Ian Martin, Vice President Asia Pacific of QIAGEN. "We have many initiatives, such as a partnership with the Malaysian Ministry of Health to enhance cervical cancer screening, work with tuberculosis control authorities to protect high-risk individuals from active TB, and support for reliable food testing such as ensuring Halal integrity. QIAGEN's mission is to make improvements in life possible, and we appreciate the welcoming business environment in Malaysia."

QIAGEN's sales in Malaysia are expanding at strong double-digit rates, contributing to the company's growth in emerging markets around the world. Molecular Diagnostics solutions, in particular, are gaining widespread acceptance in Malaysian healthcare. QIAGEN entered the country by acquiring Research Biolab Malaysia Sdn. Bhd. in 2006 and has expanded, especially into clinical testing solutions. The name was changed to QIAGEN Biotechnology Malaysia Shd. Bhd. in 2013.

The updated contact information for QIAGEN in Malaysia is as follows:

QIAGEN Biotechnology Malaysia Sdn. Bhd.
(341611M) Level 9, Tower 8, Avenue 5
Horizon Phase 2, Bangsar South
No. 8 Jalan Kerinchi
59200 Kuala Lumpur
Malaysia
Tel: +603-2718 6000
Fax: +603-2241 2010

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2015, QIAGEN employed approximately 4,300 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.